Persistent splenomegaly during imatinib therapy and the definition of complete hematological response in chronic myelogenous leukemia.

Warning

This publication doesn't include Institute of Computer Science. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	RÁČIL Zdeněk KLAMOVÁ Hana VOGLOVÁ Jaroslava FABER Edgar RÁZGA Filip ŽÁČKOVÁ Daniela BUREŠOVÁ Lucie CETKOVSKÝ Petr MAYER Jiří
Year of publication	2010
Type	Article in Periodical
Magazine / Source	American Journal of Hematology
MU Faculty or unit	Faculty of Medicine
Citation
Field	Oncology and hematology
Keywords	persistent splenomegaly; CML; CHR
Description	Splenomegaly belongs among typical findings on physical examination in patients with newly diagnosed chronic myelogenous leukemia (CML). Its disappearance is a part of achieving complete hematological response (CHR), that is nowadays (when second generation of tyrosine kinase inhibitors are available) of particular interest during imatinib treatment.
Related projects:	Functional and molecular characteristics of cancer and normal stem cells - identification of targets for novel therapeutics and therapeutic strategies